in Newswire Published on September 17, 2019

Sanofi, Boehringer Ingelheim Hit with Class Action Over Allegedly Unsafe Levels of Probable Carcinogen NDMA in Zantac [DISMISSED]

by Corrado Rizzi

Last Updated on May 12, 2023

Garza et al. v. Sanofi-Aventis U.S. LLC et al.

Filed: September 13, 2019 § 5:19-cv-05772

Zantac makers Sanofi-Aventis U.S. and Boehringer Ingelheim face a class action over the allegedly high NDMA content in the over-the-counter heartburn and indigestion drug.

May 12, 2023 – Zantac Class Action Voluntarily Dismissed

Case Spotlight

Camp Lejeune Newsletter

Stay Current

Sign Up For
Our Newsletter

New cases and investigations, settlement deadlines, and news straight to your inbox.

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Last Updated on May 12, 2023 — 9:48 AM

Corrado Rizzi

Corrado Rizzi is the Senior Managing Editor of

About is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.